Market Size of Ovarian Cancer Diagnostics and Therapeutics Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 9.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Ovarian Cancer Diagnostics and Therapeutics Market Analysis
The ovarian cancer diagnostics and therapeutics market is projected to register a CAGR of 9.5% during the forecast period.
The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. A study from ESMO Journal published in May 2021 conducted a survey in which a total of 356 centers from 54 countries across six continents participated. These centers serve 716,979 new patients with cancer every year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Hence, the data suggest that the pandemic impacted cancer care across the world severely. However, currently, the market has reached its pre-pandemic nature in terms of demand for diagnostics and therapeutics, and it is expected to witness strong growth in the coming years.
Factors such as increasing ovarian cancer cases across the world and the use of combination therapies for the treatment of ovarian cancer are expected to drive the growth of the market.
The data published by the American Cancer Society in January 2022 mentioned that ovarian cancer was the seventh most common cancer among women globally, and 4.4% of entire cancer-related mortality among women is attributed to ovarian cancer. Thus, the increasing number of cases of ovarian cancer among the population is driving the growth of the ovarian cancer diagnostics and therapeutics market.
Similarly, in March 2022, the American Cancer Society reported that the five-year survival rate for ovarian cancer with early-stage 1 detection is around 93% and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time and scope for proper treatment. However, with the increasing burden of cancer globally, people in developed countries are becoming more concerned about the disease, which is increasing the diagnosis volume and contributing to market growth. Additionally, the innovative launches by the market players are expected to drive the growth of the market. For instance, in May 2022, Inex Innovate launched the Ovarian Cancer detection test, OvaCis Rapid test, in the Southeast Asian markets.
Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period. However, the lack of awareness in emerging and low-income countries is expected to limit growth.
Ovarian Cancer Diagnostics and Therapeutics Industry Segmentation
As per the scope of the report, ovarian cancer is a type of cancer that begins in the ovaries. There are several types of ovarian cancer. Epithelial ovarian cancer is the most common type of ovarian cancer. Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women across the world.
The Ovarian Cancer Diagnostics and Therapeutics Market is Segmented by Cancer Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, and Other Cancer Types), Modality (Diagnosis (Biopsy, Blood Tests, Ultrasound, PET, CT Scan, and Other Diagnosis) and Therapeutics (Chemotherapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Other Therapeutics), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value (in USD Million) for the above segments.
| By Cancer Type | |
| Epithelial Ovarian Tumors | |
| Ovarian Germ Cell Tumors | |
| Other Cancer Types |
| By Modality | ||||||||
| ||||||||
|
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Ovarian Cancer Diagnostics and Therapeutics Market Size Summary
The ovarian cancer diagnostics and therapeutics market is poised for significant growth, driven by an increasing incidence of ovarian cancer globally and the adoption of combination therapies. The market has rebounded to its pre-pandemic state, with strong demand for diagnostics and therapeutics expected to continue. Factors such as the rising number of ovarian cancer cases and the introduction of innovative diagnostic tests, like Inex Innovate's OvaCis Rapid test, are contributing to market expansion. Despite challenges in emerging and low-income countries due to lack of awareness, the market is supported by advancements in diagnostic technologies, such as computed tomography (CT) scans, which offer high sensitivity and specificity in detecting ovarian cancer. Regulatory approvals for advanced diagnostic devices further bolster market growth.
North America, particularly the United States, is anticipated to hold a significant share of the market, supported by the presence of key industry players and increasing ovarian cancer cases. The region benefits from the concentration of top global diagnostics companies and the approval of advanced therapeutics, such as the USFDA's clearance of Cytalux, an imaging drug for ovarian cancer. The competitive landscape is dominated by major players like AstraZeneca, Boehringer Ingelheim, and Siemens Healthineers, among others. These companies are actively involved in launching new treatments and obtaining regulatory approvals, which are expected to drive market growth during the forecast period.
Ovarian Cancer Diagnostics and Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Burden of Ovarian Cancer
-
1.2.2 Use of Combination Therapies for the Treatment of Ovarian Cancer
-
-
1.3 Market Restraints
-
1.3.1 Lack of Accurate Diagnosis of Ovarian Cancer
-
1.3.2 Lack of Awareness in Emerging and Low Income Economies
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Cancer Type
-
2.1.1 Epithelial Ovarian Tumors
-
2.1.2 Ovarian Germ Cell Tumors
-
2.1.3 Other Cancer Types
-
-
2.2 By Modality
-
2.2.1 Diagnosis
-
2.2.1.1 Biopsy
-
2.2.1.2 Blood Tests
-
2.2.1.3 Ultrasound
-
2.2.1.4 PET
-
2.2.1.5 CT Scan
-
2.2.1.6 Other Diagnosis
-
-
2.2.2 Therapeutics
-
2.2.2.1 Chemotherapy
-
2.2.2.2 Radiation Therapy
-
2.2.2.3 Immunotherapy
-
2.2.2.4 Hormonal Therapy
-
2.2.2.5 Other Therapeutics
-
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Ovarian Cancer Diagnostics and Therapeutics Market Size FAQs
What is the current Ovarian Cancer Diagnostics and Therapeutics Market size?
The Ovarian Cancer Diagnostics and Therapeutics Market is projected to register a CAGR of 9.5% during the forecast period (2024-2029)
Who are the key players in Ovarian Cancer Diagnostics and Therapeutics Market?
Astrazeneca plc, Glaxosmithkline Plc, Johnson and Johnson (Janssen Pharmaceuticals), F. Hoffmann-La Roche Ltd and Siemens Healthineers AG are the major companies operating in the Ovarian Cancer Diagnostics and Therapeutics Market.
